Your Biotech Financial Model Is a Lie, And That’s Normal
Why NexiThera doesn't rebuild finance from scratch or pretend AI changes everything.
The question that landed in our CFO's inbox
"AI-designed biologics are compressing the timeline from molecule discovery to IND filing but the financial models most biotech CFOs use were built for 10-year development cycles. NexiThera's approach sits outside that assumption. Are you rebuilding the financial framework from scratch, or adapting existing models?"
It's a good question. It's also the wrong question. Why? Because it assumes there's a correct model somewhere, either the old one or a shiny new one and we just need to pick. There isn't.
The dirty secret of biotech finance
Every financial model is a fiction that investors agree to believe.
The 10-year development cycle? That's not physics. That's the average of thousands of messy, failed, delayed projects.
The 60% preclinical failure rate? That's not biology. That's what happens when you don't have systematic evidence coverage, agentic reasoning, and recursive simulation.
Legacy models don't describe reality. They describe what happened when people did things the old way.
So when someone asks "are you rebuilding finance from scratch?", they're really asking: "Do you have a credible story about time, risk, and return or do you have a spreadsheet with AI-shaped wishes?"
The NexiThera answer: neither.
We're not rebuilding finance from scratch.
We're not force-fitting AI timelines into legacy models.
We're building a dual-track model.
Track 1: Regulatory floor
For conservative investors who want to see what happens if everything goes normally, just a bit faster.
Discovery to IND in 1.5–2.5 years (not 3–5).
Preclinical failure at 40% (not 60%).
Same FDA timelines. Same regulatory reality. Just better inputs.
Track 2: Scientific upside
For investors who understand that platform biology changes the math.
Three scenarios: conservative, base, upside.
Not because we know which one will happen. Because we can show what needs to be true for each.
The gap between Track 1 and Track 2? That's where alpha lives.
The specific adjustment no one talks about
NexiThera is not a single-asset story. It's a platform.
Genovate + EpistemicOS = shared evidence graph, shared agents, shared simulations.
👉 Program #1 —> costs X.
👉 Program #2 —> costs less (data already exists).
👉 Program #3 —> costs even less (agents already calibrated).
Legacy models treat each program as an independent coin flip. That's WRONG for platform biotechs and everyone knows it, but no one has a better number. So we built one: Platform leverage ratio.
Total portfolio NPV divided by sum of individual program NPVs if built in isolation.
For NexiThera, we project 1.5–2.5x by program #5.
That's not a fantasy. That's just not discarding what you already learned.
What we are absolutely not doing
- ❌ Black-box "AI multiplier”: "Our AI is magic, so multiply everything by 3." Investors have seen that movie. It ends badly.
- ❌ Ignoring regulatory reality: FDA timelines won't compress 10x. Only discovery will. Pretending otherwise is how you burn cash waiting for a filing that isn't ready.
- ❌ Acting like biologics are small molecules: Different manufacturing, different safety profiles, different failure modes. We adjust.
The question our CFO should have been asked
The person who wrote that email was smart. But they missed the more interesting question: "How do you model the de-risking effect of shared infrastructure across programs and can you show us the evidence?"
That's the question that separates platform thinkers from asset thinkers. Because if you're just funding one molecule, use the old model. It's fine. But if you're funding a discovery engine, a system that learns, remembers, and accelerates, then the old model is worse than wrong. It's misleading.
It tells you that programs are independent. They're not.❌
It tells you that failure rates are fixed. They're not.❌
It tells you that time is linear. It's not anymore.❌
The one thing every biotech CFO should steal from us
You don't need a new model. You need two models:
- ✅ One that conservative investors trust.
- ✅ One that visionary investors understand.
- ✅ And a clear explanation of why the gap between them is real, not marketing.
That's what we gave our CFO. And the response? "That's the most honest answer I've received this year."
The bottom line
Finance models are fictions —> The question is whether your fiction is useful. Legacy models are useful for what they were built for: linear time, independent programs, stable failure rates.
They are not useful for AI-designed biologics on a platform architecture. So we didn't throw them away.
We added a second track.
Track 1 for the skeptics. Track 2 for the believers. Evidence for both.
That's not rebuilding finance from scratch. That's just not lying to ourselves.
NexiThera – Autonomous scientific discovery for next-generation therapies.
Our models are fictions. But they're honest fictions. And we can prove why.